Centessa Pharmaceuticals PLC ADR (CNTA)
Official siteBIOTECHNOLOGY
Last updated: Jun 25, 2026 at 5:00 PM ET
Centessa Pharmaceuticals PLC ADR (CNTA) Financials: Revenue, Profit and Cash Flow
Centessa Pharmaceuticals PLC ADR reported revenue of $15.00M for the fiscal year ended Dec 31, 2025. That year, net income was -$197.53M with a net margin of -1316.9%, operating cash flow was -$193.82M and free cash flow was -$194.19M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$79.24M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $15.00M | N/A | 100.0% | -1384.6% | -1316.9% |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $6.85M | N/A | 100.0% | -2499.4% | -2204.7% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Mar 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $15.00M | $0 | $6.85M | $0 | $0 | $0 | $0 |
| Gross profit | $15.00M | $0 | $6.85M | $0 | $0 | $0 | $0 |
| Research and development | $172.22M | $150.24M | $124.41M | $155.08M | $96.32M | $9.30M | $4.26M |
| Operating income | -$207.69M | -$201.06M | -$171.28M | -$212.26M | -$374.87M | -$10.44M | -$5.05M |
| Net income | -$197.53M | -$235.76M | -$151.09M | -$216.21M | -$381.90M | -$10.66M | -$5.28M |
| EBITDA | -$183.33M | N/A | -$165.43M | -$209.55M | -$139.30M | -$10.29M | -$5.05M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $15.00M | $0 | $0 | $0 | $0 | $6.85M | $0 | $0 |
| Gross profit | -$238.60K | $0 | $0 | $0 | $15.00M | $0 | $0 | $0 | $0 | $6.85M | $0 | $0 |
| Operating income | -$79.77M | -$68.47M | -$53.79M | -$54.65M | -$30.78M | -$74.58M | -$46.41M | -$43.98M | -$36.09M | -$35.18M | -$40.21M | -$47.02M |
| Net income | -$79.24M | -$66.16M | -$54.89M | -$50.34M | -$26.14M | -$111.33M | -$42.57M | -$43.82M | -$38.05M | -$36.84M | -$38.65M | -$24.89M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $7.57M by $53.73M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $687.50M | $576.80M | $360.25M | $444.31M | $629.63M | $11.72M | $19.73M |
| Current assets | $367.88M | $536.41M | $315.09M | $437.75M | $628.77M | $11.16M | $19.23M |
| Cash and equivalents | $61.30M | $383.22M | $128.03M | $393.64M | $595.08M | $7.23M | N/A |
| Total liabilities | $160.63M | $175.25M | $124.00M | $108.14M | $138.08M | $8.62M | $6.07M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $5.63M | $544.00K |
| Long-term debt | $7.57M | $108.94M | $75.70M | $69.80M | $75.70M | $0 | $3.62M |
| Shareholder equity | $526.86M | $401.55M | $236.24M | $336.17M | $491.55M | $3.10M | $13.66M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $641.76M | $687.50M | $448.30M | $492.13M | $527.85M | $576.80M | $609.72M | $398.85M | $328.17M | $360.25M | $377.36M | $392.92M |
| Total liabilities | $154.41M | $160.63M | $146.73M | $147.21M | $141.60M | $175.25M | $110.58M | $111.88M | $113.01M | $124.00M | $117.97M | $116.31M |
| Cash and equivalents | $62.43M | $61.30M | $50.81M | $44.24M | $105.16M | $383.22M | $395.03M | $127.37M | $118.22M | $128.03M | $171.50M | $145.22M |
| Shareholder equity | $487.35M | $526.86M | $301.57M | $344.92M | $386.25M | $401.55M | $499.14M | $286.96M | $215.16M | $236.24M | $259.39M | $276.61M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$193.82M | -$142.06M | -$160.34M | -$200.55M | -$136.14M | -$10.63M | -$5.83M |
| Capital expenditures | $371.00K | $34.00K | $169.00K | $1.14M | $185.98K | $0 | $0 |
| Free cash flow | -$194.19M | -$142.09M | -$160.51M | -$201.68M | -$136.33M | -$10.63M | -$5.83M |
| Share repurchases | $0 | $0 | $0 | $0 | $12.00K | $0 | $0 |
| Investing cash flow | -$418.53M | $31.27M | -$127.00M | -$931.00K | $63.25M | $0 | $0 |
| Financing cash flow | $291.53M | $364.75M | $21.12M | $457.00K | $660.07M | $1.36M | $9.01M |
Quarterly
| Line item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$72.22M | -$55.81M | -$58.31M | -$22.45M | -$57.25M | -$42.80M | -$21.39M | -$40.58M | -$37.29M | -$31.10M | -$37.39M | -$44.06M |
| Capital expenditures | $0 | $11.00K | $234.00K | $126.00K | $3 | $0 | $34.00K | $1 | $0 | $28.03K | $43.00K | $10.00K |
| Free cash flow | -$72.22M | -$55.82M | -$58.55M | -$22.58M | -$57.25M | -$42.80M | -$21.42M | -$40.58M | -$37.29M | -$31.13M | -$37.44M | -$44.07M |
Frequently Asked Questions About CNTA
What is Centessa Pharmaceuticals PLC ADR's annual revenue?
Centessa Pharmaceuticals PLC ADR reported revenue of $15.00M for the fiscal year ended Dec 31, 2025.
Is Centessa Pharmaceuticals PLC ADR profitable?
No. Centessa Pharmaceuticals PLC ADR reported net income of -$197.53M for the fiscal year ended Dec 31, 2025, with a net margin of -1316.9%.
How much free cash flow does CNTA generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$193.82M minus capital expenditures of $371.00K produced free cash flow of -$194.19M.
How much debt does Centessa Pharmaceuticals PLC ADR have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $7.57M, short-term debt of $0 and cash and equivalents of $61.30M.
What is CNTA's profit margin?
For the fiscal year ended Dec 31, 2025, Centessa Pharmaceuticals PLC ADR reported gross margin of 100.0%, operating margin of -1384.6% and net margin of -1316.9%.
CNTA pages: Overview, Financials